Paul Mueller Company (MUEL)
OTC PINK OTC PINK Primary 
MUEL Q2 Earnings Rise Y/Y Despite Margin Pressure, Backlog Strong
Paul Mueller's Q2 revenues jump 29% y/y, but lower margins weigh on earnings as strong pharmaceutical demand and a healthy backlog support the results.
Paul Mueller Q1 Earnings Fall Y/Y on Higher Costs, Revenues Rise
MUEL's Q1 earnings drop sharply y/y despite solid revenue growth, as rising project costs and delays pressure margins and weigh on profitability.
Paul Mueller Q4 Earnings Rise Y/Y on Strong Sales, Backlog Growth
MUEL posts strong Q4 results, with rising sales, higher profits and a record backlog, driving shares sharply ahead of the broader market.
Paul Mueller: Strong Q4 Results, Yet The Upside May Not Be Fully Priced In
Paul Mueller delivered record Q4 results, with 33% revenue growth and a 59% year-over-year increase in backlog. MUEL's core business is driving growth, while data center exposure remains purely optional and additive to performance. Capital allocation is disciplined: $17M in buybacks, minimal debt, and significant investment in a new manufacturing facility.
Zacks Initiates Coverage of MUEL With Neutral Recommendation
Discover why Zacks, the first on Wall Street to initiate coverage, rates MUEL as "Neutral." Explore how Paul Mueller's surging backlog and pharma-driven growth are reshaping its revenue outlook amid key execution risks.
Paul Mueller Company Is Wonderfully Compelling
Paul Mueller Company offers a compelling value proposition with strong growth, a robust balance sheet, and deep operating diversification. MUEL has achieved significant revenue and profit expansion, driven primarily by its Industrial Equipment segment and increased demand in pharma, food, and water purification. Backlog surged to $250.4 million in Q3 2025, indicating strong forward revenue visibility and further earnings growth potential.
